Core Viewpoint - Jiangsu Aidi Pharmaceutical (688488.SH) announced a plan to acquire minority shareholder equity in its subsidiary, Nanjing Nanda Pharmaceutical, which will increase its direct shareholding from 51.13% to 73.36% [1][3] Group 1: Acquisition Details - Aidi Pharmaceutical plans to raise up to 185 million yuan through a simplified procedure to fund the acquisition, with 130 million yuan allocated for acquiring 22.23% of Nanda Pharmaceutical's equity and 55 million yuan for working capital [1] - The acquisition is expected to enhance Aidi's control over Nanda Pharmaceutical and optimize financial performance, maximizing synergies between the two companies [4][10] Group 2: Market Potential - The demand for stroke treatment is anticipated to surge, with acute ischemic stroke cases in China projected to rise from 4.1 million in 2023 to 4.9 million by 2027 [4] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035 [4] Group 3: Product Pipeline - Aidi's new drugs, AD108 injection and ADB116 injection, are positioned to become significant profit growth drivers, targeting acute ischemic stroke treatment [4] - Aidi's HIV drug, Enomirac, has shown strong sales potential, with revenue from HIV drugs reaching 211 million yuan in the first three quarters of 2025, a 57.12% increase year-on-year [6][7] Group 4: International Expansion - Aidi Pharmaceutical is accelerating its international market expansion, with its HIV drug Enomirac approved for sale in Zanzibar, marking a significant milestone for Chinese-developed HIV drugs in Africa [9] - The company is also advancing its pipeline of innovative drugs, including a new HIV integrase inhibitor and long-acting pre-exposure prophylaxis drugs, which are in various stages of clinical trials [10]

Group 1 - The core point of the article is that Jiangsu Aidi Pharmaceutical Group announced a plan to raise up to 185 million yuan through a simplified procedure for issuing A-shares, primarily to acquire a 22.23% stake in its subsidiary Nanjing Nanda Pharmaceutical Co., Ltd. for approximately 130.06 million yuan and to supplement working capital with 55 million yuan [1][2] - The chairman of Aidi Pharmaceutical, Fu Helian, stated that this move is a significant step towards focusing on the core business and enhancing competitive strength, aimed at long-term strategic development [1] - Nanda Pharmaceutical specializes in thrombolytic drugs and low molecular weight heparin raw materials, being one of the few companies in China that holds production licenses for both raw materials and injectable formulations [1] Group 2 - Aidi Pharmaceutical previously acquired a 19.96% stake in Nanda Pharmaceutical in July 2022 and plans to further purchase an additional 31.16% stake in 2024, thereby gaining control over Nanda Pharmaceutical [2] - The acquisition of the additional 22.23% stake will enhance Aidi Pharmaceutical's control over Nanda Pharmaceutical, promoting strategic management upgrades and improving financial performance [2] - Aidi Pharmaceutical has maintained rapid growth in the HIV treatment sector for three consecutive years and is focused on advancing its core research pipeline and establishing a comprehensive commercialization system for new HIV drugs [2]